Redcare Pharmacy stock: Berenberg lifts target from EUR 94 to EUR 102 for Redcare Pharmacy stock
Published on 10/23/2026 at 17:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget and guidance update
- Berenberg lifted its Redcare Pharmacy target from EUR 94.00 to EUR 102.00 on October 7, 2026.
- Full-year 2026 revenue growth guidance rose to 16.00 to 18.00 percent from 15.00 to 17.00 percent.
- Redcare Pharmacy stock costs EUR 78.40 at Lang & Schwarz on October 23, 2026 at 5:05 p.m. CEST, 0.06 percent below the Xetra close of October 22, 2026.
- Redcare Pharmacy will publish its third-quarter 2026 interim statement on October 29, 2026.
Redcare Pharmacy (ISIN NL0012044747) is tied to Berenberg's EUR 102.00 target after the bank lifted it from EUR 94.00 on October 7, 2026, as onvista reported. The new target is 30.10 percent above the EUR 78.40 price at Lang & Schwarz on October 23, 2026 at 5:05 p.m. CEST, while the stock stood 0.06 percent below the Xetra close of October 22, 2026.
Guidance points to German Rx growth
Redcare Pharmacy raised full-year 2026 total revenue growth guidance to 16.00 to 18.00 percent from 15.00 to 17.00 percent on September 28, 2026. The company's German prescription-drug revenue target also rose to EUR 730.00 million to EUR 760.00 million from EUR 680.00 million to EUR 720.00 million, according to the Redcare Pharmacy release. Preliminary German prescription-drug revenue grew 56.00 percent year over year in the third quarter of 2026, while the adjusted EBITDA margin stayed between 2.50 and 3.00 percent in the full-year outlook.
Stock sits below its yearly high
At EUR 78.40 on October 23, 2026 at 5:05 p.m. CEST, Redcare Pharmacy was 5.03 percent below its 52-week high of EUR 82.55 and 159.60 percent above its 52-week low of EUR 30.20. The same quotation showed a day range of EUR 77.40 to EUR 79.90 and volume of 32,021 shares. Its market capitalization was EUR 1.6 billion.
What dates matter next?
Redcare Pharmacy will publish its interim statement for the third quarter of 2026 and hold its quarterly conference call on October 29, 2026, according to the September 28 release. The company is part of the SDAX and has listed its shares on the regulated Frankfurt market since 2016.
Comparison with peers
Redcare Pharmacy: down 0.06 percent, market capitalization EUR 1.6 billion. DocMorris (SIX, CHF): down 0.64 percent, market capitalization CHF 788.6 million. GoodRx (Nasdaq, USD): down 1.24 percent, market capitalization USD 1.2 billion.
Price remains close to the daily midpoint
The current quotation places Redcare Pharmacy below its 52-week high while the upcoming October 29 report provides the next dated operating checkpoint. The market capitalization remains materially above DocMorris but close to GoodRx in scale.
Redcare Pharmacy was trading at EUR 78.40 at Lang & Schwarz on October 23, 2026 at 5:05 p.m. CEST, down 0.06 percent versus the Xetra close of October 22, 2026 at EUR 78.45. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy stock facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Primary exchange: Frankfurt Stock Exchange
- Price Lang & Schwarz (as of October 23, 2026, 5:05 p.m. CEST): EUR 78.40
- Change versus Xetra close: minus 0.06 percent
- Xetra close (October 22, 2026): EUR 78.45
- Market capitalization: EUR 1.6 billion (as of October 23, 2026)
- 52-week range: EUR 30.20-EUR 82.55 (as of October 23, 2026)
- Sector / Industry: Consumer discretionary / Online pharmacy
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
